Clinical trials: open to volunteers, in Sweden
Kidney Disease
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation).
- Trial name
- NCT06963827
- Testing
- Mezagitamab
- Where
- 186 sites in United States, Argentina and 24 more
- Volunteers
- 347 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
- Trial name
- NCT07222332
- Testing
- Baricitinib
- Where
- 130 sites in United States, Australia and 18 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Insomnia, Depression
Acute Psychological Sleep Stabilisation for Patients Hospitalised With Depression
Disturbed sleep occurs in almost all patients in psychiatric inpatient care, and although it is well known that comorbid sleep disorders in depression often persist after treatment of depression and also increase the risk of new…
- Trial name
- NCT06145555
- Testing
- Acute psychological sleep stabilization, Sleep hygiene education
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Karolinska Institutet
Stroke, Stroke (in Patients With Atrial Fibrillation)
Thrombolysis in Factor Xa-inhibitors Trial
This study looks at whether stroke patients who take FXa inhibitors (a type of blood thinner) can safely receive clot-busting treatment (IVT).
- Conditions
- Stroke, Stroke (in Patients With Atrial Fibrillation), Ischemic Stroke, Acute Ischemic Stroke
- Trial name
- SIFT (NCT06878066)
- Testing
- thrombolysis therapy
- Where
- 21 sites in Denmark, Norway and 1 more
- Volunteers
- 300 people
- Sponsor
- Guri Hagberg
Advanced Non-small Cell Lung Cancer, HER2 Mutation
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations.
- Trial name
- SOHO-02 (NCT06452277)
- Testing
- Sevabertinib, Pembrolizumab, Cisplatin
- Where
- 279 sites in United States, Argentina and 34 more
- Volunteers
- 444 people
- Sponsor
- Bayer
Ischemic Heart Disease, Ischemic Coronary Artery Disease
Optical Coherence Tomography in Acute Vessel Evaluation
The purpose is to investigate if a strategy of routine OCT based diagnosis and guidance of PCI improves clinical outcomes compared with a standard strategy of guidance by angiography in patients presenting with ACS
- Conditions
- Ischemic Heart Disease, Ischemic Coronary Artery Disease, ACS (Acute Coronary Syndrome)
- Trial name
- OCTAVE (NCT07422688)
- Testing
- Angiographic Guided PCI, OCT Guided PCI
- Where
- 28 sites in Belgium, Denmark and 10 more
- Volunteers
- 3,000 people
- Sponsor
- Aarhus University Hospital Skejby
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
- Trial name
- NCT06128629
- Testing
- NTLA-2001
- Where
- 138 sites in United States, Argentina and 24 more
- Volunteers
- 1,200 people
- Sponsor
- Intellia Therapeutics
Arrhythmia, Bradycardia
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival…
- Conditions
- Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
- Trial name
- PPR (NCT00271180)
- Testing
- Device
- Where
- 338 sites in United States, Australia and 33 more
- Volunteers
- 20,000 people
- Sponsor
- Medtronic
Cancer Related Cardiovascular Toxicity, Anthracycline Related Cardiotoxicity in Breast Cancer
3D Versus 2D Strain Echocardiography for Early Detection of Cardiotoxicity During Cancer Therapy
Some cancer treatments, such as anthracycline chemotherapy and HER2-targeted therapy, can damage the heart (cardiotoxicity). If heart damage is detected early, heart-protective treatment can be started and cancer treatment can…
- Conditions
- Cancer Related Cardiovascular Toxicity, Anthracycline Related Cardiotoxicity in Breast Cancer, Breast Cancer, Cardiotoxicity
- Trial name
- SAFE-HEART (NCT07916337)
- Where
- Sweden
- Volunteers
- 130 people
- Sponsor
- Region Skane
Symptomatic Genetic Dilated Cardiomyopathy
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM).
- Trial name
- KINSHIP-DCM (NCT07210723)
- Testing
- danicamtiv
- Where
- 79 sites in United States, Belgium and 9 more
- Volunteers
- 332 people
- Sponsor
- Kardigan, Inc.
Symptomatic Genetic Dilated Cardiomyopathy (DCM)
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Danicamtiv is an investigational medication, which means it is still being studied and has not been approved. The purpose of this study is to learn how well danicamtiv works, how safe it is, how well people can take it when used…
- Trial name
- KINSHIP-OLE (NCT07771465)
- Testing
- Danicamtiv
- Where
- 78 sites in United States, Belgium and 9 more
- Volunteers
- 332 people
- Sponsor
- Kardigan, Inc.
Bronchiectasis
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
This study is for adults and adolescents who are at least 12 years old and have bronchiectasis. People can participate if they completed a previous study with the study medicine called verducatib.
- Trial name
- NCT07915219
- Testing
- verducatib
- Where
- 383 sites in United States, Argentina and 37 more
- Volunteers
- 1,500 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
- Trial name
- BARICADE-DELAY (NCT07222137)
- Testing
- Baricitinib
- Where
- 112 sites in United States, Australia and 17 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to…
- Trial name
- SUNRAY-02 (NCT06890598)
- Testing
- Olomorasib, Pembrolizumab, Durvalumab
- Where
- 368 sites in United States, Australia and 27 more
- Volunteers
- 700 people
- Sponsor
- Eli Lilly and Company
Parenting Intervention, Anger
Digital Behavioral Parenting Programs With and Without Added Emotion Regulation Strategies to Manage Anger in Parenting
This pilot randomized controlled trial evaluates the feasibility, acceptability, and preliminary effects of two digital parenting interventions for parents experiencing difficulties with anger in parenting.
- Conditions
- Parenting Intervention, Anger, Emotion Regulation Difficulties, Parenting Behaviour
- Trial name
- NCT07795684
- Testing
- Online Behavioral Parent Training Program, Online Behavioral Parent Training + Emotion Regulation Program
- Where
- Sweden
- Volunteers
- 90 people
- Sponsor
- Karolinska Institutet
Immune Thrombocytopenic Purpura (ITP)
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed.
- Trial name
- NCT06722235
- Testing
- Mezagitamab
- Where
- 124 sites in United States, Australia and 16 more
- Volunteers
- 171 people
- Sponsor
- Takeda
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Continuous Controlled Cooling for Prevention of Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of certain types of chemotherapy and can cause numbness, tingling, pain, and other symptoms in the hands and feet.
- Trial name
- COOL-tax (NCT07917026)
- Testing
- Continuous Controlled Cooling of the Hands and Feet
- Where
- Sweden
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Vastra Gotaland Region
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC.
- Trial name
- SUNRAY-01 (NCT06119581)
- Testing
- LY3537982, Pembrolizumab, Cisplatin
- Where
- 415 sites in United States, Australia and 27 more
- Volunteers
- 1,264 people
- Sponsor
- Eli Lilly and Company
Heart Failure, Cardiovascular Risk Factors
Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)
The DECISION trial aims to evaluate the efficacy of an artificial intelligence (AI)-powered system, Willem™, for improving the detection of heart failure (HF) in primary care settings by interpreting electrocardiograms (ECGs).
- Trial name
- DECISION (NCT07113223)
- Testing
- Willem™ platform ECG assessment
- Where
- 5 sites in Spain, Sweden
- Volunteers
- 1,968 people
- Sponsor
- Idoven 1903 S.L.
Colorectal Neoplasms
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy…
- Trial name
- OrigAMI-3 (NCT06750094)
- Testing
- Amivantamab, Cetuximab, Bevacizumab
- Where
- 251 sites in United States, Australia and 24 more
- Volunteers
- 700 people
- Sponsor
- Janssen Research & Development, LLC